Navigation Links
CareFusion Initiates Class I Recall of EnVe Ventilators
Date:10/19/2011

SAN DIEGO, Oct. 19, 2011 /PRNewswire/ -- CareFusion (NYSE: CFN), a leading global medical device company, issued the following update regarding its recall of 128 EnVe™ ventilators affecting 29 customers. The FDA has classified this action as a Class I recall.

The voluntary recall only affects EnVe ventilators manufactured between December 2010 and May 2011 and therefore, has no affect on the company's current product production or shipping processes.

On September 12, the company sent an urgent Medical Device Recall Notification to customers stating the identified potential risks associated with the EnVe ventilators. The issues include: a potential delay in resuming ventilation after reconnection; a potential automatic reset; and a potential for disconnection upon transport. Failure to adequately ventilate may lead to hypoxia or hypercarbia, which may result in serious neurological injury or death. A Class I recall is defined as a reasonable probability of serious adverse health consequences or death associated with use of the defective units.

In the notification letter, customers were provided serial numbers of affected devices. This information is available at http://www.carefusion.com/customer-support/alerts-notices/medical-device-recall-enve-ventilator.aspx.

CareFusion is conducting a field corrective action to update the hardware and software on affected ventilators. The company determined the root cause for each issue and is committed to updating each device in a timely manner with minimal disruption to customers.

Instructions to customers

Customer inquiries related to this action should be addressed to CareFusion Technical Support at 800-554-8933.

Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA's MedWatch Program: by mail at MedWatch, HF-2, FDA 5600 Fishers Lane, Rockville, MD 20852-9787; by phone at 1-800-332-1088; by fax at 1-800.FDA.0178 or at www.fda.gov/medwatch.

About CareFusion

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined™ services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.


'/>"/>
SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Launches New Emergency Transport Ventilator
2. B. Braun Medical Sues CareFusion for Patent Infringement
3. CareFusion Reports Fourth Quarter and Fiscal 2011 Results
4. CareFusion and ResMed Announce Distribution Agreement for U.S. Hospital Market
5. CareFusion Will Host an Earnings Conference Call on Aug. 8 to Discuss the Results for the Fourth Quarter and Fiscal 2011
6. CareFusion to Acquire Pharmacy Automation Innovator Rowa
7. CareFusion Reports Third Quarter Rise in Revenue, Earnings
8. CareFusion Will Host an Earnings Conference Call on May 5 to Discuss the Results for the Third Quarter Fiscal 2011
9. CareFusion Acquires Technology for Sorting and Managing Dangerous Pharmaceutical Waste
10. CareFusion Announces Departure of Chief Operating Officer
11. CareFusion Completes Sale of Onsite Services Instrument Management and Repair Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... SAN FRANCISCO , March 29, 2017 /PRNewswire/ ... an option agreement with Bionure Farma, S.L. for ... BN201 and to BN119 in the field of ... million plus sales-based royalties. The agreement provides ... stage assets with a differentiated product profile. Under ...
(Date:3/29/2017)... 29, 2017   Royal Philips (NYSE: ... technology, and PathAI, a company that develops artificial ... aim to develop solutions that improve the precision ... other diseases. The partnership aims to build deep ... of artificial intelligence to be applied to massive ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... Immunotherapy has emerged ... number of cancers and is touted to be the next revolution in our fight ... has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):